Patent application number | Description | Published |
20080269180 | Androgen Treatment in Females - A method of improving cumulative embryo score may comprise administering an androgen to a human female for at least about four consecutive months followed by harvesting and fertilizing oocytes and forming embryos. A method of increasing the quantity of fertilized oocytes in one cycle of in vitro fertilization may comprise administering an androgen to a human female for at least about four consecutive months, harvesting and fertilizing the oocytes. A method of normalizing ovarian DHEA may include administering an androgen for at least about four consecutive months. A method of decreasing the time to pregnancy and increasing the rate of pregnancy by administering an androgen for at least about two months. A method of decreasing miscarriage rates may comprise administering an androgen for at least about two months to a female. Moreover, a method of decreasing aneuploidy rates in human embryos may comprise administering an androgen to a female for at least about two months. | 10-30-2008 |
20100113407 | ANDROGEN TREATMENT IN FEMALES - The present invention is directed to a method of using dehydroepiandrosterone (DHEA) to treat a human female with diminished ovarian reserve. The method includes measuring a baseline follicle stimulating hormone (FSH) level of the human female, and when the baseline FSH level is below about 40.0 mIU/ml, administering about 75 milligrams of DHEA per day to the female for at least four months to treat ovarian follicles in at least one ovary of the female to improve human folliculogenesis during the at least four months. The present invention further is directed to a method of restoring the ovarian environment of an older human female to that of a younger human female. The method includes administering about 75 milligrams of DHEA per day to the female for at least four months. | 05-06-2010 |
20110020795 | ANALYZING THE FMR1 GENE - A method of predicting a degree of risk of early ovarian aging of a young female. The method includes analyzing the female's FMR1 gene, wherein the FMR1 gene has a first allele and a second allele; determining the number of triple CGG repeats on each of the first and second alleles; defining a normal range of triple CGG repeats; comparing the number of triple CGG repeats on each of the first and second alleles to the normal range. If the triple CGG repeat numbers for both of the first and second alleles are within the normal range, then the female is at minimal risk for early ovarian aging. If the triple CGG repeat number for one of the first and second alleles is outside of the normal range and the other one of the first and second alleles is within the normal range, then the first and second alleles are heterozygous and the female is at increased risk for early ovarian aging. If the triple CGG repeat numbers for both of the first and second alleles are outside of the normal range, then the first and second alleles are homozygous and the female is also at an increased risk for early ovarian aging. | 01-27-2011 |
20110159494 | Analyzing the FMR1 Gene - A method of predicting a degree of risk of autoimmunity in a human female is disclosed. The method may include analyzing the female's FMR1 gene, wherein the FMR1 gene has a first allele and a second allele, determining the number of triple CGG repeats on each of the first and second alleles; defining a normal range of triple CGG repeats; and comparing the number of triple CGG repeats on each of the first and second alleles to the normal range. If the triple CGG repeat number for one of the first and second alleles is in the normal range and the triple CGG repeat number for the other one of the first and second alleles is less than the lower boundary of the normal range, then the female is at increased risk of autoimmunity. Additionally, a method of predicting pregnancy chances for a human female is disclosed. The method may include analyzing the female's FMR1 gene, wherein the FMR1 gene has a first allele and a second allele; determining the number of triple CGG repeats on each of the first and second alleles; defining a normal range of triple CGG repeats; and comparing the number of triple CGG repeats on each of the first and second alleles to the normal range. If the triple CGG repeat number for one of the first and second alleles is in the normal range and the triple CGG repeat number for the other one of the first and second alleles is less than the lower boundary of the normal range, then the female has decreased chances of pregnancy. | 06-30-2011 |
20110207708 | Androgen Treatment in Females - The present invention is directed to a method of using dehydroepiandrosterone to treat a human female with diminished ovarian reserve. The method includes administering about 25 milligrams three times a day of dehydroepiandrosterone per day to the female for at least four weeks to reduce human embryo aneuploidy. The present invention further is directed to a method of treating a human female with diminished ovarian reserve to improve the female's diminished ovarian reserve. | 08-25-2011 |
20120129957 | ANALYZING THE FMR1 GENE - A method of screening a human for risk of malignancies is disclosed. The method may include isolating the human's FMR1 gene, wherein the FMR1 gene has a first allele and a second allele, measuring the number of triple CGG repeats on each of the first and second alleles, wherein the measuring step is conducted through use of an assay, and identifying the human as at risk for cancer when the triple CGG repeat number for at least one of the first and second alleles is less than 26. | 05-24-2012 |
20130012569 | METHOD OF TREATMENTS RELATED TO THE FMR1 GENE - A method of treating a human to reduce the risk of malignancies or limit the spread of malignancies includes administering an FMR1 inhibitor to the human to block expression of an FMR1 gene. The FMR1 inhibitor blocks FMR1 genes in the human with at least one of two alleles with less than 26 triple CGG repeats. | 01-10-2013 |
20140011787 | ANDROGEN TREATMENT IN FEMALES - Method of improving ovarian reserve in a human female with diminished ovarian reserve as measured by the female's anti-Müllerian hormone level. The method may include evaluating a first anti-Müllerian hormone level of the female, administering an androgen, such as dehydroepiandrosterone or testosterone, to the female for at least about one month, and then evaluating a second anti-Müllerian hormone level of the female. Change in the anti-Müllerian hormone level is indicative of change in the ovarian reserve, e.g., when the second anti-Müllerian hormone level is greater than the first anti-Müllerian hormone level, the ovarian reserve has improved. The androgen administration may continue until the second anti-Müllerian hormone level is greater than the first anti-Müllerian hormone level by a desired percentage or amount. | 01-09-2014 |
20140038930 | ANDROGEN TREATMENT IN FEMALES - Method of using an androgen, such as dehydroepiandrosterone (DHEA) or testosterone, to improve human folliculogenesis. The method includes measuring a baseline follicle stimulating hormone (FSH) level of the human female, and when the baseline FSH level is below about 40.0 mIU/ml, administering about 75 milligrams of the androgen per day to the female for at least four months to treat ovarian follicles in at least one ovary of the female to improve human folliculogenesis during the at least four months. The present invention further is directed to a method of restoring the ovarian environment of an older human female to that of a younger human female. The method includes administering about 75 milligrams of an androgen per day to the female for at least four months. | 02-06-2014 |
20140100264 | METHODS OF TREATMENT RELATING TO THE FMR1 GENE - A method of treating a human female to increase embryo survival and embryo quality includes administering an FMR1 enhancer to a human embryo to cause an increase in expression of an FMR1 gene. The FMR1 enhancer increases the expression of FMR1 genes in the human embryo with at least one of two alleles with less than 26 triple CGG repeats. | 04-10-2014 |
20140206756 | DETECTION OF INFERTILITY RISK AND PREMATURE OVARIAN AGING - Method of early detection of risk of infertility and ovarian aging in and treatment of a human female who has not experienced infertility and is not otherwise indicated to have premature ovarian aging. A number of CGG repeats on each allele of the isolated FMR1 gene is measured by using an assay, and a testing regimen is performed only when the determined number of CGG repeats on one of the FMR1 gene alleles is less than 26. The testing regimen includes periodically measuring serum level of a hormone related to fertility, such as Anti-Müllerian Hormone, Follicle Stimulating Hormone and/or estradiol over a period of about three to eight years and, after each measurement, determining if the measured serum level is less than a set confidence interval for a human female of the same age of the female. If so, the human female is treated for premature ovarian aging. | 07-24-2014 |
20140235540 | ANDROGEN AND GONADOTROPIN TREATMENT IN FEMALES - A method of treating a human female with an androgen and a gonadotropin to improve at least one of the human female's infertility, reproductive outcomes and oocyte yield is disclosed. The method may include treating the female with an androgen and a gonadotropin in combination. The androgen may be administered for more than six weeks and the gonadotropin may be administered in a regular low dosage over a period of time longer than two weeks. The method may include inducing ovulation in the female by administering gonadotropins to stimulate ovulation and/or induce ovulation. The method may include multiple additional inductions of ovulation, each within 120 days of the previous induction of ovulation. | 08-21-2014 |
20140243585 | SCREENING OF OOCYTE DONOR CANDIDATES BASED ON THE FMR1 GENE - Method of selecting oocyte donor candidates for oocyte donation. A number of triple CGG repeats on each allele of the isolated FMR1 gene is measured by using an assay, and an oocyte donor is selected for oocyte donation only if both alleles of the isolated FMR1 gene have more than 26 CGG repeats. | 08-28-2014 |
Patent application number | Description | Published |
20080264947 | FOOD PACKAGE WITH LID - A food package has a container and a lid. The lid includes a planar surface and a convex dome that is above the planar surface. A transparent window in the convex dome attracts the attention of consumers since it is raised relative to the remainder of the lid. The lid also includes a concave dome that frames a raised logo or raised text within the dome. By framing the logo, the concave dome helps to direct a consumer's attention to the logo or text and helps to protect the logo or text from wear. | 10-30-2008 |
20110200716 | LID AND CONTAINER - A container lid comprises a top, substantially planar surface, means for coupling with a top of a container, a depressed area, a raised area, and a hinge area. The top, substantially planar surface is elongated to define two opposite longitudinal edges and two opposite lateral edges, and each of the two opposite lateral edges extends between and is shorter than each of the two longitudinal edges. The depressed area is surrounded by and extends below the top, substantially planar surface. The raised area is surrounded by and extends above the top, substantially planar surface. The raised area is positioned nearest one of the two opposite lateral edges and the depressed area is positioned nearest the other one of the two opposite lateral edges. The hinge area extends laterally across the top, substantially planar surface and is positioned between the depressed area and the raised area. | 08-18-2011 |
Patent application number | Description | Published |
20110152742 | Pull-Activated Tampon Applicator - A pull-activated applicator includes a barrel, a pledget, a finger grip, and a deployment element. The pledget includes a withdrawal string and is located within the barrel. The barrel, the pledget, and the deployment element are configured such that application of a force to the deployment element in a first direction deploys the pledget and withdrawal string from the barrel in a second direction generally opposite the first direction. | 06-23-2011 |
20120165599 | Vaginal Insert Device Having a Support Portion with Plurality of Foldable Areas - Generally, a vaginal insert device used to treat urinary incontinence is disclosed. The vaginal insert device includes a support portion, a stabilizing portion, a removal device, and at least one fluid passageway extending though the support portion. The substantially cylindrical support portion has a distal end and a proximal end. In addition, the support portion has a plurality of foldable areas extending from the distal end to the proximal end. Desirably, the plurality of foldable areas helically curve as the plurality of foldable areas extend from the distal end to the proximal end. The largest outer circumference of the support portion has an insertion diameter when the plurality of foldable areas are compressed and foldable inward and an in-use diameter wherein the plurality of foldable areas are extended outward into a maximum in-use diameter position. Desirably, the in-use diameter is larger than the insertion diameter. | 06-28-2012 |
20120165601 | Vaginal Insert Device Having a Support Portion with Plurality of Struts - A vaginal insert device including a support portion, a stabilizing portion, a removal device, and at least one fluid passageway extending though the support portion is disclosed. The vaginal insert relaxes in the vagina to deliver outward compression force against the bladder neck via the anterior vaginal wall to assist prevention of urinary stress incontinence. The substantially cylindrical support portion has a distal end, a proximal end, and a hollow interior section with a plurality of struts extending from the distal end to the proximal end. Desirably, the plurality of struts helically curve as the plurality of struts extend from the distal end to the proximal end. The largest circumference of the support portion has an insertion diameter when the plurality of struts are twisted together and an in-use diameter wherein the plurality of struts are extended outward into a convex position larger than the insertion diameter. | 06-28-2012 |
20150025438 | Pull-Activated Tampon Applictor - A pull-activated applicator includes a barrel, a pledget, a finger grip, and a deployment element. The pledget includes a withdrawal string and is located within the barrel. The barrel, the pledget, and the deployment element are configured such that application of a force to the deployment element in a first direction deploys the pledget and withdrawal string from the barrel in a second direction generally opposite the first direction. | 01-22-2015 |